Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Millennium, Compugen In Deal For Protein Pathway Software

March 27, 2002

By Rachelle H.B. Fishman

Ester Neurosciences Gets OK For Myasthenia Gravis Trials

Feb. 27, 2002

By Rachelle H.B. Fishman

Teva’s Copaxone Failure In MS Attributed To Low Relapse Rate

Feb. 22, 2002

By Rachelle H.B. Fishman

Budget Cuts Sidetrack Plan For Israeli Biotech Institute

Jan. 9, 2002

By Rachelle H.B. Fishman

Novartis Enlists Optimata To Analyze New Drug Candidates

Jan. 9, 2002

By Rachelle H.B. Fishman

MS Drugs Spur 33 Percent Growth In Israeli Biotech

May 30, 2001

By Rachelle H.B. Fishman

Mindsense Biosystems Secures $2M For Biomarkers Technology

May 23, 2001

By Rachelle H.B. Fishman

Compugen Contributes Data To Gene Ontology Consortium

May 16, 2001

By Rachelle H.B. Fishman

Israeli Biotech Industry Keeps Going Despite Political Turmoil

May 16, 2001

By Rachelle H.B. Fishman

Clal Biotechnology Establishes Center To Help Israeli Start-Ups

March 21, 2001

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...